CD8A and neoplasm: The ex vivo anti-tumor immunity exhibited that the combination treatment also significantly suppressed Gal-9 in splenic DCs (Fig. 6b), reduced PD-1 on the CD8+ T lymphocytes (Fig. 6i), and increased tumor-Ag-specific T cell response (Fig. 6j), thus leading to PTIT.